Maxbien Pharma Profile
Key Indicators
- Authorised Capital ₹ 22.00 Cr
as on 11-12-2024
- Paid Up Capital ₹ 10.53 Cr
as on 11-12-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -26.43%
(FY 2023)
- Profit -109.06%
(FY 2023)
- Ebitda -100.11%
(FY 2023)
- Net Worth 4.62%
(FY 2023)
- Total Assets -5.53%
(FY 2023)
About Maxbien Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 22.00 Cr and a paid-up capital of Rs 10.53 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Maxbien Pharma Private Limited India is Divya Singam as COMPANY SECRETARY. Satyanarayana Goluguri, Dumpa Reddy, and Vasu Vajja serve as directors at the Company.
- CIN/LLPIN
U24299TG2020PTC143389
- Company No.
143389
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Sep 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Maxbien Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Divya Singam | Company Secretary | 22-Sep-2023 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyanarayana Goluguri  | Director | 01-Sep-2020 | Current |
| Dumpa Reddy | Director | 22-May-2021 | Current |
| Vasu Vajja | Director | 31-Dec-2020 | Current |
Financial Performance of Maxbien Pharma.
Maxbien Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 26.43% decrease. The company also saw a substantial fall in profitability, with a 109.06% decrease in profit. The company's net worth moved up by a moderate rise of 4.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maxbien Pharma?
In 2023, Maxbien Pharma had a promoter holding of 98.97% and a public holding of 1.03%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Svs Facility Management Services Private LimitedActive 9 years 21 days
Dumpa Reddy and Vasu Vajja are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Maxbien Pharma?
Maxbien Pharma has a workforce of 7 employees as of Nov 14, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maxbien Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maxbien Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
